Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
erlotinib + thalidomide
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of erlotinib and thalidomide. Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), used primarily for treating non-small cell lung cancer and pancreatic cancer. Thalidomide is an immunomodulatory agent used for multiple myeloma and erythema nodosum leprosum. When combined, thalidomide can decrease the serum concentration of erlotinib, potentially reducing its efficacy.
02
Targets
Beyond the preview
Go deeper on erlotinib + thalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on erlotinib + thalidomide.